The FY22 Defense Appropriations Act provides funding for the Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY22 PRCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. 

Congressionally Directed Topic Areas:  The FY22 PRCRP appropriation will provide funds for research into cancers not addressed in the other CDMRP cancer programs (https://cdmrp.army.mil/researchprograms).  To be considered for funding, applications for the FY22 PRCRP must address at least one of the FY22 PRCRP Topic Areas as directed by Congress.  Research applications in the areas of breast, kidney, lung, prostate, pancreatic, ovarian, and rare cancer or melanoma are prohibited and will not be accepted.  The inclusion of the individual rare cancer research program shall not prohibit the PRCRP from funding the below-mentioned cancers or cancer subtypes that may be rare by definition.

The FY22 PRCRP Topic Areas are:

The FY22 PRCRP Military Health Focus Areas are listed below:

It is central to the vision and mission of the PRCRP that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, Veterans, and other military beneficiaries (i.e., family members of retirees).  The FY22 PRCRP requires all applications to answer at least one of the following Military Health Focus Areas:

• Environmental/exposure risk factors associated with cancer

• ·        Gaps in cancer research that may affect mission readiness:

○       Gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military Service Members, Veterans, and their beneficiaries

○       Gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military Service Members, Veterans, and their beneficiaries

FY22 PRCRP Overarching Challenges

The PRCRP has developed a strategy to address multiple issues in cancer research over the spectrum of different cancer topics considered for funding.  These Overarching Challenges are critical gaps in cancer research, care, and/or patient outcomes that, if addressed, will advance the mission readiness of U.S. military members affected by cancer and will improve quality of life by decreasing the burden of cancer on Service Members, their families, Veterans, and the American public.  To reference the PRCRP Overarching Challenges, see https://cdmrp.army.mil/prcrp.

Press Release: 2022 Peer Reviewed Cancer Research Program, Congressionally Directed Medical Research Program (army.mil)

Convergent Science Cancer Consortium Development Award – Letter of Intent due August 17, 2022

PI for Coordinating Center (Consortium Director): Investigators at or above the level of Associate Professor (or equivalent); must have a proven record of accomplishment of leading and scientific ability to direct and oversee a multi[1]institutional research effort. Co-PI for the Research Site: Investigators at or above the level of Assistant Professor (or equivalent); must have a proven record of accomplishment of collaboration

Letter of Intent is required. An invitation to submit a full application is not required.

• Supports novel approaches to ending cancer through convergent science research.

• Emphasis is on the development of a convergent science infrastructure – Coordinating Center.

• Proof of principle (convergent science) research projects support.

• Must address at least one of the FY22 PRCRP Military Health Focus Areas.

• Must address at least three different FY22 PRCRP Topic Areas.

• Must address at one of the FY22 PRCRP Overarching Challenges.

• Clinical trials are not allowed.

• ·        The maximum allowable funding for the entire period of performance is $2,500,000 for direct costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism can be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca.

The FY22 Defense Appropriations Act provides funding for the Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY22 PRCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. 

Congressionally Directed Topic Areas:  The FY22 PRCRP appropriation will provide funds for research into cancers not addressed in the other CDMRP cancer programs (https://cdmrp.army.mil/researchprograms).  To be considered for funding, applications for the FY22 PRCRP must address at least one of the FY22 PRCRP Topic Areas as directed by Congress.  Research applications in the areas of breast, kidney, lung, prostate, pancreatic, ovarian, and rare cancer or melanoma are prohibited and will not be accepted.  The inclusion of the individual rare cancer research program shall not prohibit the PRCRP from funding the below-mentioned cancers or cancer subtypes that may be rare by definition.

The FY22 PRCRP Topic Areas are:

The FY22 PRCRP Military Health Focus Areas are listed below:

It is central to the vision and mission of the PRCRP that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, Veterans, and other military beneficiaries (i.e., family members of retirees).  The FY22 PRCRP requires all applications to answer at least one of the following Military Health Focus Areas:

• Environmental/exposure risk factors associated with cancer

• ·        Gaps in cancer research that may affect mission readiness:

○       Gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military Service Members, Veterans, and their beneficiaries

○       Gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military Service Members, Veterans, and their beneficiaries

FY22 PRCRP Overarching Challenges

The PRCRP has developed a strategy to address multiple issues in cancer research over the spectrum of different cancer topics considered for funding.  These Overarching Challenges are critical gaps in cancer research, care, and/or patient outcomes that, if addressed, will advance the mission readiness of U.S. military members affected by cancer and will improve quality of life by decreasing the burden of cancer on Service Members, their families, Veterans, and the American public.  To reference the PRCRP Overarching Challenges, see https://cdmrp.army.mil/prcrp.

Press Release: 2022 Peer Reviewed Cancer Research Program, Congressionally Directed Medical Research Program (army.mil)

Behavioral Health Science Award – Letter of Intent due July 12, 2022

Independent investigator with a faculty-level appointment (or equivalent).

• ·    Letter of Intent is required. An invitation to submit a full application is not required.
• ·    Supports high-reward concepts that spans the spectrum of behavioral health science including prevention, survivorship, quality of life, and psychosocial research related to cancer.
• ·    Must address at least one of the FY22 PRCRP Topic Areas.
• ·    Must address at least one of the FY22 PRCRP Military Health Focus Areas.
  • ·    Must address at least one of the FY22 PRCRP Overarching Challenges.
  • ·    Preliminary data required.
  • ·    Pilot clinical trials are allowed.
  • ·    The maximum allowable funding for the entire period of performance is $1,000,000 for direct costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is 4 years.

Career Development Award – Fellow Option – Letter of Intent due July 12, 2022

Principal Investigator (PI): Independent investigators at or above the level of Research Assistant Professor or Instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research.

Letter of Intent is required. An invitation to submit a full application is not required.

• Supports early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.

• Must address at least one of the FY22 PRCRP Topic Areas.

• Must address at least one of the FY22 PRCRP Military Health Focus Areas.

• Must address at least one of the FY22 PRCRP Overarching Challenges.

• Preliminary data are not required.

• Clinical trials are not allowed.

The maximum allowable funding for the entire period of performance is $400,000 for direct costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is 3 years.

Career Development Award –  Virtual Cancer Center Scholar Option – Letter of Intent due July 12, 2022

• ·    PI: Independent investigators at or above the level of Assistant Professor or Instructor (or equivalent) on tenure track and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.
• ·    Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research.
• ·    Letter of Intent is required. An invitation to submit a full application is not required.
• ·    Supports the addition of new early-career investigators (Scholars) to the unique, interactive virtual cancer center focused on fostering the next generation of cancer researchers. •
• ·     The Scholar will be required to interact within the virtual cancer center and with the Cancer Center Director and Deputy Director.
• ·     The Scholar Option provides intensive mentoring, national networking, and a peer group for junior faculty. • Scholars must demonstrate significant accomplishments.
• ·     A Career Guide – an experienced cancer researcher with cancer funding – is required. • The Career Guide is not required to be at the same institution as the Scholar.
• ·     Must address at least one of the FY22 PRCRP Topic Areas.
• ·    Must address at least one of the FY22 PRCRP Military Health Focus Areas.
• ·    Preliminary data are not required. • Clinical trials are not allowed.
• ·    The maximum allowable funding for the entire period of performance is $800,000 for direct costs.
• ·    Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·    The maximum period of performance is 4 years.

Translational Team Science Award – Letter of Intent due July 12, 2022

At least two, and a maximum of three, PIs must partner in one overarching correlative or translational research study.

At least one of the PIs is encouraged to be a military or US Department of Veterans Affairs investigator.

• ·    Letter of Intent is required. An invitation to submit a full application is not required.
• ·    Emphasizes multi-PI, multidisciplinary collaborations.
• ·    Supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research.
• ·    Not intended to support high-throughput screenings, sequencing, etc.
• ·    Must address at least one of the FY22 PRCRP Topic Areas.
• ·    Must address at least one of the FY22 PRCR Overarching Challenges.
  • ·    Must address at least one of the FY22 PRCRP Military Health Focus Areas.
  • ·    Preliminary data are required.
  • ·    Clinical Trials are allowed.
  • ·        The maximum allowable funding for the entire period of performance is $2,500,000 for direct costs.
  • ·        Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • The maximum period of performance is 4 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism can be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca.

Alberta’s firefighters, police officers, paramedics, sheriffs, corrections officers and emergency health care workers often deal with stressful, dangerous and traumatic situations. This stress has a negative impact on first responders and emergency health care workers. They often experience post-traumatic stress injuries (PTSI) at significantly higher rates than the general population.

The Supporting Psychological Health in First Responders (SPHIFR) grant program has 2 separate funding streams:

• Stream 1 (Services) provides funding for non-profit organizations that provide services to first responders and emergency health care workers living with or at risk for PTSI.
• Stream 2 (Research) provides funding to researchers engaged in applied research that generates evidence on prevention or intervention for first responders and emergency health care workers living with or at risk for PTSI.

The FY22 Defense Appropriations Act is anticipated to provide funding for the SCIRP to support innovative, high-impact spinal cord injury (SCI) research.¹  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY22 SCIRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY22 SCIRP must address one or more of the following Focus Areas^†:

• ·        Preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
• ·        Identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies
• ·        Developing, testing, and validating promising interventions to address bowel, genitourinary, neuropathic pain, cardiopulmonary, or autonomic dysfunction in people with SCI
• ·        Investigating psychosocial issues relevant to people with SCI, their families, and/or their care-partners
• ·        Rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after SCI

Funding Opportunities-FY22 SCIRP, Congressionally Directed Medical Research Programs (CDMRP), US DoD (army.mil)

Clinical Trial Award – Preproposal due May 23, 2022

Principal Investigator (PI): Investigators at all academic levels (or equivalent)

Optional Early-Career Partnering PI:

An independent, early-career investigator within 10 years after completion of terminal degree

• ·        Preproposal is required; application submission is by invitation only.

Translational Research Award – Preproposal due May 23, 2022

PI: Investigators at all academic levels (or equivalent)

Optional Early-Career Partnering PI:

An independent, early-career investigator within 10 years after completion of terminal degree

• ·        Preproposal is required; application submission is by invitation only.
• ·        Funds studies that accelerate the movement of promising ideas in SCI research into clinical applications.

• Community Collaborations in Research: Applications are expected to name at least one community partner (e.g., SCI Lived Experience Consultant, representative of community-based organization) who will provide advice and consultation throughout the planning and implementation of the research project.

• Preliminary data required.

• The SCIRP Translational Research Award may include a pilot clinical trial ONLY as a part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.

• Early-Career Partnering PI Option

The maximum allowable funding for the entire period of performance is $1.25M for direct costs.

• Early-Career Partnering PI Option: Maximum allowable funding for the entire period of performance is $1.35M for direct costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is 3 years.

Investigator-Initiated Research Award – Preproposal due May 23, 2021

PI: Investigators at all academic levels (or equivalent)

Optional Early-Career Partnering PI:

An independent, early-career investigator within 10 years after completion of his/her terminal degree

• ·        Preproposal is required; application submission is by invitation only.

Funds research that has the potential to make an important contribution to SCI research, patient care, and/or quality of life.

• Studies focused exclusively on target identification are discouraged.

• Preliminary data required.

• Clinical trials are not allowed.

• Early-Career Partnering PI Option

The maximum allowable funding for the entire period of performance is $0.50M for direct costs.

• Early-Career Partnering PI Option: Maximum allowable funding for the entire period of performance is $0.60M for direct costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

¹ Funding is provided through the FY22 appropriation for Peer-reviewed Spinal Cord Research

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca .

Fisheries and Oceans Canada (DFO) provides funding to build expertise in ocean and freshwater science and technology in areas that support the mission of the Department to increase our understanding of ocean and freshwater environments. Through this, we seek to better protect, sustain and restore fisheries resources as well as the aquatic ecosystems that support them.

The Department is seeking projects that deliver scientific research and related scientific activities that support evidence-based decision making and public understanding about the health of marine and freshwater ecosystems. Related scientific activities complement and extend scientific research by contributing to the generation, dissemination and application of scientific and technological knowledge. Examples of this include:

• data collection and integration
• ocean and freshwater monitoring
• data analyses
• modelling and hypothesis testing
• scientific capacity building (Indigenous recipients only)
• communication of science in support of ocean literacy

The overarching objective of this funding opportunity is to address the pressing needs of PSP organizations and support service providers in providing effective and evidence-based supports for PSP experiencing PTSI.

The specific objectives of this funding opportunity are:

• To contribute to the improved health of PSP with PTSI by generating relevant and timely evidence around the merit, validity, and appropriateness of the two targeted support systems identified through this program.
• To assess the potential impacts of these two targeted support systems on PSP, including through novel and innovative research approaches directly using the core technologies/methodologies in place at the Research and Coordination hubs.
• To contribute to the development of sustainable support systems for PSP by catalyzing research on potentially effective support models, and through the development of evidence summaries, best practices, and guidance documents for the targeted support models identified through this program.

CIHR’s HIV/AIDS and STBBI Research Initiative, with strategic leadership from the CIHR Institute of Infection and Immunity (III), will provide funding to applicants requesting support to attend the 24th International AIDS Conference (AIDS 2022). AIDS 2022, which is the largest gathering on HIV and AIDS in the world, is being organized by the International AIDS Society (IAS) and will take place from July 29-August 2, 2022 in Montreal, Canada. This award is intended to support individuals participating at the conference either in person or virtually.